Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Shanghai Miracogen Signs $125 Million Deal to Use Synaffix ADC Technologies

publication date: Apr 10, 2019

Miracogen, a Shanghai biopharma with clinical-stage antibody drug conjugates, acquired non-exclusive rights to two ADC technologies developed by Dutch biotech Synaffix in a $125 million deal. Synaffix says the two technologies, GlycoConnect™ and HydraSpace™, create ADCs with enhanced efficacy and tolerability. Miracogen, which licensed the technologies for use in its next clinical candidate, will make upfront and potential milestone payments that total $125 million, plus royalties. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China